+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Chemotherapy for advanced (stage IIIB and stage IV) non-small cell lung cancer: the Hong Kong perspective



Chemotherapy for advanced (stage IIIB and stage IV) non-small cell lung cancer: the Hong Kong perspective



Respirology 3(3): 145-149



Non-small cell lung cancer (NSCLC) accounts for about 80% of all primary lung cancers, and 60% of cases present as advanced stages IIIB and IV disease. Traditionally, treatment of stages IIIB and IV disease was only symptomatic (including radiotherapy) and supportive care, and cytotoxic chemotherapy was relatively ineffective. Our initial clinical trials, using MACC, FuAM, FAM, Hi-FAM and cisplatin-VP16, gave response rates of 5-20% and a stabilization rate of 7-25%, with no impact on median survival. Our most recent chemotherapy regimen MIP (mitomycin-C, ifosfamide and cisplatin) proved to be more effective with a 44% response rate and a 28% stabilzation rate, and produced a significantly longer median survival (32 weeks) than best supportive care alone (19.5 weeks, P< 0.05). The response rate further increased to 62.5% with dose intensification and GM-CSF support. Chemotherapy can now be recommended to motivated, well-informed patients with good performance status in institutions with experience in cancer chemotherapy on a protocol basis. The most recent addition of new effective cytotoxic agents such as paclitaxel, docetaxel, gemitabine and vinorelbine gave promising results in NSCLC, and optimal combinations and dose schedules are being defined by multicentred studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045500924

Download citation: RISBibTeXText

PMID: 9767612

DOI: 10.1111/j.1440-1843.1998.tb00113.x


Related references

Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer (Stage Iiib or Iv) with a Higher T Stage (> T2). Oncology 63(2): 173-179, 2002

P-438 A retrospective analysis of prognostic factors and rreatment outcomes of different chemotherapy regimens in patients with locally advanced (Stage IIIB) and metastatic (Stage IV) non-small cell lung cancer (NSCLC): A single Egyptian institution's experience. Lung Cancer 49: S231-S232, 2005

Sequential chemotherapy and radiotherapy for initial management of Stage IIIA and Stage IIIB non-small cell lung cancer induction chemotherapy. Lung Cancer 7(1-2): 77-84, 1991

Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion. Oncology 63(2): 173-179, 2002

Two patients with advanced non-small cell lung cancer (stage IIIB) who still responded very well to combined chemotherapy and radiotherapy. Nederlands Tijdschrift Voor Geneeskunde 149(23): 1289-1293, 2005

Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results. European Journal of Cardio-Thoracic Surgery 9(6): 305-309, 1995

Induction chemotherapy in locally advanced stage IIIA/IIIB non-small cell lung cancer Paclitaxel/carboplatin vs mitomycin C/ifosfamide/cisplatin. European Respiratory Journal Suppl. 10(25): 154S, Sept, 1997

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer ChemoTherapy and Pharmacology 65(2): 227-234, 2011

Stage IIIB non-small cell lung cancer. Interventional bronchoscopy in stage IIIB bronchial carcinoma. Revue des Maladies Respiratoires 23(5 Pt 3): 16s68-16s71, 2007

Cisplatin-based chemotherapy in elderly patients with advanced stage (IIIB and IV) non-small cell lung cancer patients. Neoplasma 58(4): 348-351, 2011

Cisplatin-based chemotherapy in elderly patients with advanced stage (Iiib and Iv) non-small cell lung cancer patients. Neoplasma 58(4): 348-351, 2011

Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. Journal of Thoracic Oncology 3(8): 894-901, 2008

Chemotherapy of stage IIIB and IV non-small-cell lung cancer. Annals of Oncology 6 Suppl 3: S41-S44, 1995

Prospective randomized study of chemotherapy versus chemotherapy with immunotherapy in stage IIIB or IV non-small-cell lung cancer. Acta Haematologica (Basel) 103(Suppl. 1): 55, 2000

Advanced radiotherapy techniques in stage IIIB non-small cell lung cancer. European Journal of Cancer Suppl.s 5(5): 269-276, 2007